Search research articles
Contact Us
Filters
Showing results (81-90 of 91) with videos related to
Page
of 10
Sort By:
The New England Journal of Medicine
|
March 25, 2026
Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer
Wungki Park, Anup Kasi, Alexander I Spira, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 29, 2025
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study
Mariam Alexander, Ying Cheng, Se-Hoon Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2021
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
Keunchil Park, Eric B Haura, Natasha B Leighl, et al.
Nature Medicine
|
March 28, 2024
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results
Amy R Rappaport, Chrisann Kyi, Monica Lane, et al.
Nature Medicine
|
August 15, 2022
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results
Christine D Palmer, Amy R Rappaport, Matthew J Davis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 4, 2025
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A
Benjamin Besse, Koichi Goto, Yongsheng Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 10, 2024
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study
Natasha B Leighl, Hiroaki Akamatsu, Sun Min Lim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 28, 2024
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
E Felip, B C Cho, V Gutiérrez, et al.
The New England Journal of Medicine
|
September 9, 2025
Overall Survival with Amivantamab-Lazertinib in <i>EGFR</i>-Mutated Advanced NSCLC
James Chih-Hsin Yang, Shun Lu, Hidetoshi Hayashi, et al.
Cancer Research
|
August 29, 2025
TNG260 is a Small-Molecule CoREST Inhibitor that Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy
Leanne G Ahronian, Soumyadip Sahu, Minjie Zhang, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 91) with videos related to
Sort By:
Page
of 10
The New England Journal of Medicine
|
March 25, 2026
Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer
Wungki Park, Anup Kasi, Alexander I Spira, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 29, 2025
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study
Mariam Alexander, Ying Cheng, Se-Hoon Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2021
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
Keunchil Park, Eric B Haura, Natasha B Leighl, et al.
Nature Medicine
|
March 28, 2024
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results
Amy R Rappaport, Chrisann Kyi, Monica Lane, et al.
Nature Medicine
|
August 15, 2022
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results
Christine D Palmer, Amy R Rappaport, Matthew J Davis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 4, 2025
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A
Benjamin Besse, Koichi Goto, Yongsheng Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 10, 2024
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study
Natasha B Leighl, Hiroaki Akamatsu, Sun Min Lim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 28, 2024
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
E Felip, B C Cho, V Gutiérrez, et al.
The New England Journal of Medicine
|
September 9, 2025
Overall Survival with Amivantamab-Lazertinib in <i>EGFR</i>-Mutated Advanced NSCLC
James Chih-Hsin Yang, Shun Lu, Hidetoshi Hayashi, et al.
Cancer Research
|
August 29, 2025
TNG260 is a Small-Molecule CoREST Inhibitor that Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy
Leanne G Ahronian, Soumyadip Sahu, Minjie Zhang, et al.
Page
of 10